関連する実験動画
Updated: May 5, 2026

04:34
Mouse Complete Stasis Model of Inferior Vena Cava Thrombosis
Published on: June 15, 2011
18.0K
閉経後の女性の非致死性静脈血栓症との遺伝的変異の関連性
Nicholas L Smith1, Lucia A Hindorff, Susan R Heckbert
1Department of Epidemiology, University of Washington, Seattle, WA 98101, USA. nlsmith@u.washington.edu
JAMA
|February 8, 2007
まとめ
凝固遺伝子の遺伝的変異は,閉経後の女性の静脈血栓症 (VT) リスクについて研究されました. 5つの単一ヌクレオチドポリモルフィズム (SNP) は静脈VTリスクと関連しており,3つはさらなる研究を必要とする新しい発見でした.
科学分野:
- 遺伝学 遺伝学とは
- トロンボシス研究研究
- エピデミオロジー エピデミオロジー
背景:
- 静脈血栓症 (VT) リスクにおける遺伝的変異の役割は完全に理解されていません.
- 以前の研究は,凝固タンパク質を特徴づけたが,VTへの遺伝的貢献を全面的に調査したわけではない.
研究 の 目的:
- 24の候補遺伝子の共通遺伝的変異と,非致死性静脈栓塞 (VT) の発生リスクとの関連を調査する.
- 閉経後の女性に焦点を当てて,静脈動脈療法に対する遺伝的予備性を理解します.
主な方法:
- 集団ベースのケース・コントロール研究が行われました.
- 最初のVTイベント (n=349) とマッチングされたコントロール (n=1680) を含む30~89歳の閉経後の女性.
- ハプロタイプと単一核性子ポリモルフィズム (SNP) を用いて共通の遺伝的変異を分析し,誤発見率 (q値) によって重要性が評価された.
主要な成果:
- 組織因子経路阻害遺伝子のグローバルバリエーションは,静脈VTリスクと関連する傾向を示した.
- 5つの有意な単一ヌクレオチドポリモルフィズム (SNP) 関連がVTリスクと因子V,因子XI,およびタンパク質C遺伝子の間で特定されました.
- 5つの重要なSNPのうち3つは新しい発見を表し,2つは以前に報告された関連性を確認しています.
結論:
- 5つのSNPは,複数のテストに調整した後に静脈栓塞のリスクと関連していました.
- 3つの新しいSNP結合は,独立した集団で複製する必要があります.
- 閉経後の女性におけるVTリスクに影響を与える遺伝的要因を特定することは,標的型予防戦略にとって極めて重要です.
関連する概念動画
Genome-wide Association Studies-GWAS
12.6K
Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
GWAS does not require the identification of the target gene involved in...
12.6K
Principles of Pharmacogenetics: Types of Genetic Variants
138
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
138
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
159
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
159
Venous Thrombosis I: Introduction
822
Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...
822
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies
469
The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...
469
Venous Thrombosis III: Interprofessional Care
482
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
482

